Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection

Transplantation

Volumn 62, Issue 1, 1996, Pages 38-42

  Midtvedt, Karsten ^a,b   Tafjord, Anne Beate ^a   Hartmann, Anders ^a   Eide, Trond Cato ^a   Holdaas, Hallvard ^a   Nordal, Knut Paul ^a   Draganov, Branimir ^a   Sødal, Gunnar ^a   Leivestad, Torbjørn ^a   Fauchald, Per ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; OKT 3;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; LIVING DONOR; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; CREATININE; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG RESISTANCE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MUROMONAB-CD3;

EID: 8944249300     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199607150-00008     Document Type: Article

References (28)

1. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535.
2. Goldstein G, Norman DJ, Shield CF III, et al. OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatment. In: Meryman HT, ed. Transplantation: approaches to graft rejection. New York: Liss, 1986: 239.
3. Kahana L, Baxter J. OKT3 rescue in refractory renal rejection. Nephron 1987; 46 (suppl 1): 34.
4. Norman DJ, Barry JM, Bennett WM, et al. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Am J Kidney Dis 1988; 11: 90.
5. D'Alessandro AM, Pirsch JD, Melzer JS, et al. Use of OKT3 in kidney, pancreas, and liver transplantation. Transplant Proc 1990; 22: 1748.
6. Ponticelli C, Rivolta E, Tarantino A, De Vecchi A, Vegeto A. Rescue of severe steroid-resistant rejection with OKT3. Transplant Proc 1987; 19: 1908.
7. Tvedegaard E, Olgaard K. Orthoklone OKT3 as rescue treatment for steroid-resistant and recurrent acute rejection in clinical renal transplantation. Transplant Proc 1990; 22: 217.
8. Hesse UJ, Wienand P, Baldamus C, Arns W. Preliminary results of a prospective randomized trial of ALG vs OKT3 for steroidresistant rejection after renal transplantation in the early postoperative period. Transplant Proc 1990; 22: 2273.
9. Chiu A, Landdsberg D, Cameron EC, Manson ADC, Shackelton C. The effect of induction ALG (MALG) on the outcome of steroid-resistant rejection treated with OKT3 in renal transplant patients. Transplant Proc 1991; 23: 1039.
10. Norman DJ, Barry JM, Bennett WM, et al. OKT3 for induction immunosuppression in renal transplantation: a comparison study of high versus low doses. Transplant Proc 1991; 23: 1052.
11. Alloway R, Kotb M, Gaber LW, Vera S, Boskey F, Gaber AO. Standard versus low-dose OKT3 in induction therapy of cadaveric renal transplants: comparison of outcome data versus OKT3 dose and serum levels. Clin Transplant 1992; 46: 468.
12. Rubin RH, Cosimi AB. Therapy, both immunosuppressive and antimicrobial, for the transplant patient in the 1990s. In: Brent L, Sells RA, eds. Organ transplantation: current clinical and immunological concepts. London: Baillie're Tindall, 1989: 71.
13. Bia MJ, Flye MW. Infectious complications in renal transplant patients. In: Flye MW, ed. Principles of organ transplantation. Philadelphia: Saunders, 1989: 294.
14. Light JA, Johnson J, Khawand N, et al. Sequential immunosuppression: three years' experience in 240 cadaveric renal trans-plants. Transplant Proc 1991; 23: 1032.
15. Frey DJ, Mats AJ, Gillingham KJ, et al. Sequential therapy: a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaveric renal allograft recipients. Transplantation 1992; 54: 50.
16. Chou S, Norman DJ. Effect of OKT3 antibody therapy on cytomegalovirus reactivation in renal transplant recipients. Trans-plant Proc 1985; 17: 2755.
17. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 1991; 23: 1106.
18. Schweizer RT, Roper L, Hull D, Bartus SA. Low-dose OKT3 for cadaveric renal transplantation. Transplant Proc 1992; 24: 2592.
19. Brinchmann JE, Leivestad T, Vartdal F. Quantification of lymphocyte subsets based on positive immunomagnetic selection of cells directly from blood. J Immunogenet 1989; 16: 177.
20. Solez K, Axelsen RA, Bendiktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
21. Wong JT, Eylath AA, Ghobrial I, Colvin RB. The mechanism of anti-CD3 monoclonal antibodies. Transplantation 1990; 50: 683.
22. Caillat-Zucman S, Blumenfeld N, Legendre C, et al. The OKT3 immunosuppressive effect. Transplantation 1990; 49: 156
23. Niebel W, Metz KA, Albrecht KH, et al. Histologic findings and kidney graft outcome in patients with steroid-resistant rejections before and after OKT3 therapy. Transplant Proc 1990; 22: 1764.
24. Sumrani N, Delaney V, Rajpoot D, Tejani A, Butt K, Hong J. OKT3 in severe early rejection: predictor for reversal in renal transplant recipients. Transplant Proc 1990; 22: 1750.
25. Hricik DE, Mayes JT, Schulak JA. Inhibition of anti-OKT3 antibody generation by cyclosporine: results of a prospective randomized trial. Transplantation 1990; 50: 237.
26. Raffaele P, Pouteil-Noble C, Lefrancois N, et al. Influence of a randomized monoclonal or polyclonal program of therapy on cytomegalovirus infection in kidney transplantation. Transplant Proc 1991; 23: 1361.
27. Lefrancois N, Raffaele P, Martinenghi S, et al. Prophylactic polyclonal versus monoclonal antibodies in kidney and pancreas transplantation. Transplant Proc 1990; 22: 632.
28. Steinmuller DR, Hayes JM, Novick AC, et al. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation 1991; 52: 67.